Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
作者信息
Wang Chih-Wen, Yu Ming-Lung
机构信息
Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
School of Medicine and Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):606-609. doi: 10.3350/cmh.2024.1078. Epub 2024 Dec 3.
Abstract
摘要
相似文献
1
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".重新审视慢性乙型肝炎的治疗指征：TORCH-B 延续性研究的见解：关于“轻度转氨酶升高的慢性乙型肝炎抗病毒治疗：TORCH-B 试验的延续性研究”的社论
Clin Mol Hepatol. 2025 Apr;31(2):606-609. doi: 10.3350/cmh.2024.1078. Epub 2024 Dec 3.
2
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".慢性乙型肝炎患者丙氨酸氨基转移酶轻度升高时对核苷（酸）类似物的治疗反应：致编辑的信，关于“丙氨酸氨基转移酶轻度升高的慢性乙型肝炎抗病毒治疗：TORCH-B试验的延续性研究”
Clin Mol Hepatol. 2025 Apr;31(2):e140-e142. doi: 10.3350/cmh.2024.0960. Epub 2024 Dec 3.
3
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial.针对轻度转氨酶升高的慢性乙型肝炎的抗病毒治疗：TORCH-B试验的一项延续性研究。
Clin Mol Hepatol. 2025 Jan;31(1):213-226. doi: 10.3350/cmh.2024.0640. Epub 2024 Oct 17.
4
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.替诺福韦酯单药治疗初治和经治的慢性乙型肝炎患者。
Clin Mol Hepatol. 2015 Mar;21(1):41-8. doi: 10.3350/cmh.2015.21.1.41. Epub 2015 Mar 25.
5
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial.替诺福韦二吡呋酯每日 1 次治疗初治台湾慢性乙型肝炎和丙氨酸氨基转移酶（氨基转移酶）轻度升高患者（TORCH-B）：一项多中心、双盲、安慰剂对照、平行分组、随机试验。
Lancet Infect Dis. 2021 Jun;21(6):823-833. doi: 10.1016/S1473-3099(20)30692-7. Epub 2021 Jan 29.
6
Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".简化和扩大慢性乙型肝炎治疗的趋势：证据不断增加：关于“轻度转氨酶升高的慢性乙型肝炎抗病毒治疗：TORCH-B试验的一项延续性研究”的社论
Clin Mol Hepatol. 2025 Apr;31(2):603-605. doi: 10.3350/cmh.2024.0929. Epub 2024 Oct 29.
7
Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".扩大慢性乙型肝炎的治疗适用范围：权衡益处、局限性与医疗可及性：致关于“轻度转氨酶升高的慢性乙型肝炎抗病毒治疗：TORCH-B试验的一项延续性研究”的社论的信函
Clin Mol Hepatol. 2025 Apr;31(2):e169-e172. doi: 10.3350/cmh.2024.1138. Epub 2024 Dec 23.
8
Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.从加拿大公共支付方角度评估替诺福韦酯治疗慢性乙型肝炎的成本效果。
Pharmacoeconomics. 2011 Dec;29(12):1075-91. doi: 10.2165/11589260-000000000-00000.
9
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.对于慢性乙型肝炎患者，从恩替卡韦或核苷（酸）联合治疗转换为替诺福韦艾拉酚胺治疗。
Liver Int. 2020 Jul;40(7):1578-1589. doi: 10.1111/liv.14482. Epub 2020 Apr 30.
10
Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.在共价闭合环状DNA检测不到的慢性乙型肝炎患者中，核苷/核苷酸类似物停药后乙肝病毒DNA的反弹
JHEP Rep. 2020 Mar 29;2(3):100112. doi: 10.1016/j.jhepr.2020.100112. eCollection 2020 Jun.
引用本文的文献
1
Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".扩大慢性乙型肝炎的治疗适用范围：权衡益处、局限性与医疗可及性：致关于“轻度转氨酶升高的慢性乙型肝炎抗病毒治疗：TORCH-B试验的一项延续性研究”的社论的信函
Clin Mol Hepatol. 2025 Apr;31(2):e169-e172. doi: 10.3350/cmh.2024.1138. Epub 2024 Dec 23.
本文引用的文献
1
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial.针对轻度转氨酶升高的慢性乙型肝炎的抗病毒治疗：TORCH-B试验的一项延续性研究。
Clin Mol Hepatol. 2025 Jan;31(1):213-226. doi: 10.3350/cmh.2024.0640. Epub 2024 Oct 17.
2
Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase.不确定期慢性乙型肝炎患者中的肝细胞癌
J Viral Hepat. 2024 Dec;31 Suppl 2(Suppl 2):27-35. doi: 10.1111/jvh.13914. Epub 2024 May 8.
3
The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area.代谢功能障碍相关脂肪性肝病与病毒性肝炎对肝脏疾病严重程度的相互作用：病毒流行地区的一项大型基于社区的研究。
J Gastroenterol Hepatol. 2024 Jan;39(1):193-201. doi: 10.1111/jgh.16363. Epub 2023 Sep 20.
4
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.抗病毒治疗可大幅降低处于不确定阶段的慢性乙型肝炎感染患者患肝癌的风险。
Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16.
5
Global burden of hepatitis B virus: current status, missed opportunities and a call for action.全球乙型肝炎病毒负担：现状、错失的机会和行动呼吁。
Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):524-537. doi: 10.1038/s41575-023-00760-9. Epub 2023 Apr 6.
6
Perspectives on current controversial issues in the management of chronic HBV infection.慢性乙型肝炎病毒感染管理中当前有争议问题的观点。
J Gastroenterol. 2022 Nov;57(11):828-837. doi: 10.1007/s00535-022-01918-z. Epub 2022 Sep 2.
7
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?如何实现乙肝功能性治愈：停止核苷（酸）类似物，加用干扰素或开发新药？
J Hepatol. 2022 Jun;76(6):1249-1262. doi: 10.1016/j.jhep.2021.11.024.
8
KASL clinical practice guidelines for management of chronic hepatitis B.《慢性乙型肝炎管理的KASL临床实践指南》
Clin Mol Hepatol. 2022 Apr;28(2):276-331. doi: 10.3350/cmh.2022.0084. Epub 2022 Apr 1.
9
Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation".乙型肝炎 e 抗原阴性慢性乙型肝炎的有限核苷（酸）类似物治疗：从“选择”到“积极推荐”。
Kaohsiung J Med Sci. 2022 Apr;38(4):295-301. doi: 10.1002/kjm2.12518. Epub 2022 Mar 9.
10
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines.用于预测 HCC 的风险评分，以及抗病毒治疗对治疗指南灰色地带 CHB 患者的获益。
Hepatol Int. 2021 Dec;15(6):1421-1430. doi: 10.1007/s12072-021-10263-x. Epub 2021 Nov 6.
Zotero 插件